Products for Research Use Only
RegisterLogin

Efavirenz

CAT: 0804-HY-10572-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10572-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a Ki of 2.93 nM and exhibits an IC95 of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture[1].
CAS Number
154598-52-4
Product Name Alternative
DMP 266; EFV; L-743726
UNSPSC
12352005
Hazard Statement
H242, H302, H360, H410
Target
Autophagy; Endogenous Metabolite; HIV; Parasite; Reverse Transcriptase
Type
Reference compound
Related Pathways
Anti-infection; Autophagy; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection; Cancer
Assay Protocol
https://www.medchemexpress.com/Efavirenz.html
Purity
99.93
Solubility
DMSO : ≥ 38 mg/mL
Smiles
ClC1=CC=C(NC(O[C@]2(C#CC3CC3)C(F)(F)F)=O)C2=C1
Molecular Formula
C14H9ClF3NO2
Molecular Weight
315.68
Precautions
H242, H302, H360, H410
References & Citations
[1]Young SD, et al. L-743, 726 (DMP-266) : a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1995 Dec;39 (12) :2602-5.|[2]Held DM, et al. Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. J Biol Chem. 2006 Sep 1;281 (35) :25712-22.|[3]Grobler JA, et al. HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem. 2007 Mar 16;282 (11) :8005-10.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
HIV-1

Alternative Products

CatalogName
FC30275-01Efavirenz

Popular Products